High Precision Peptide-MHC Class I CARs Enhance In Vivo Killing ofTargeted CD8 T Cells to Prevent Type 1 Diabetes in Novel RIP-mOVA Model
Francis, M. P.; Hibler, W.; Yarnell, M.; Singh, N.; Kedl, R. P.; Burchill, M. A.; Fry, T.; Nakayama, M.
Show abstract
Progress has been made to address refractory T cell-mediated diseases with chimeric antigen receptor (CAR) T cell platforms, with the need more specifically target pathogenic cells being addressed by peptide-MHC (pMHC) CAR T cells. However, progress to date has largely been limited to peptide-MHC Class II (pMHC-II) CARs for the targeting of autoreactive CD4 T cells in multiple models. Here, we develop the first single molecule peptide-MHC Class I-{beta}2 microglobulin CAR platform to demonstrate the proof of concept for depletion of antigen-specific CD8 T cells and compare the in vitro and in vivo functionality to a traditional scFv-based CAR that also targets the TCR. We demonstrate that while the scFv CAR is more rapidly and robustly activated by target CD8 T cells in vitro, the greater precision offered by pMHC-I CARs results in greater efficacy in multiple in vivo models. Additionally, we developed a novel adjuvanted ovalbumin vaccination with adoptive transfer model to induce type 1 diabetes (T1D) in RIP-mOVA mice using a polyclonal, polyepitopic T cell population. We demonstrate that our pMHC-I platform depletes SIINFEKL-reactive T cells and that control of the immune response to the dominant SIINFEKL epitope can control a broader antigenic response.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The spontaneous neoantigen-specific CD4+ T cell response to a growing tumor is functionally and phenotypically diverse. 95%
- Tumor-Specific CD8+ T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating Lymphocytes 95%
- Domain Binding and Isotype Dictate the Activity of Anti-human OX40 Antibodies 94%
Similar papers in this journal
- CD3e-immunotoxin spares CD62L(lo) Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3e(hi) T cells. 95%
- Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance 95%
- Naive and in vitro-activated primary mouse CD8+ T cells retain in vivo immune responsiveness after electroporation-based CRISPR/Cas9 genetic engineering 95%
Similar papers in this journal
- Treg cells maintain selective access to IL-2 and immune homeostasis despite substantially reduced CD25 function 95%
- Establishment of CD8+ T cell thymic central tolerance to tissue-restricted antigen requires PD-1 95%
- Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T cells 94%
Similar papers in this journal
- Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory 94%
- Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination With Nivolumab 94%
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 94%
Similar papers in this journal
- Transplantation Elicits a Clonally Diverse CD8+ T Cell Response That is Comprised of Potent CD43+ Effectors 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 95%
- Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.